Comprehensive answers regarding mitochondrial health, ubiquitin proteasome biology, mitophagy regulation, and Myto Health’s discovery and diagnostic platforms.
Mitochondria are the major source of cellular energy currency (ATP) and a signaling hub that orchestrates multiple cellular processes essential to cellular health. Damage to mitochondrial integrity and function is associated with many age-related diseases including neurodegenerative diseases, cardiac diseases, and muscle weakness.
Early diagnosis and intervention can help prevent or slow down the progression of mitochondrial diseases thereby improving the quality of life.
Mitochondrial diseases are diseases that affect different organs of the body where the cells fail to make adequate energy due to a dysfunction of the mitochondria. Age is a major factor in the decline of mitochondrial quality and many mitochondrial diseases are age related.
Genetic alterations, aging and environmental factors are primary risk factors for mitochondrial dysfunction.
Mitochondrial diseases can be diagnosed by screening for genetic mutations, mitochondrial function as well as the function of key regulatory proteins associated with mitochondrial health.
Mitophagy is the cell’s quality control mechanism where it removes damaged mitochondria and generates healthy mitochondria. Mitophagy can be regulated by naturally occurring molecules as well as by synthetic compounds.
Mitobiogenesis is the process by which cells make new and healthy mitochondria. A complex network of gene transcription and protein synthesis coordinates the production of new mitochondria. Mitobiogenesis is also amenable to regulation by nutraceuticals and pharmaceuticals.
Failure to remove damaged mitochondria by mitophagy and impairment in mitobiogenesis leads to the development of mitochondrial diseases. A reduction in cellular energy level, accumulation of reactive oxygen species, damaged proteins, cell death inducing signals, aberrant inflammatory response all contributes to the disease pathology.
Myto Health is developing nutraceuticals and pharmaceuticals for improving mitochondrial health to treat and or prevent age related mitochondrial diseases. In addition, Myto Health is also offering blood-based diagnostic biomarkers for aging and neurodegeneration.
Myto Health technology engine is driven by collection of tools to discover drugs and nutraceuticals and blood-based diagnostic biomarkers for aging and neurodegeneration by interrogating ubiquitin pathway enzymes such as ubiquitin ligases.
Myto Health has developed an AI assisted algorithm to predict the structure and subsequent function of your proteins responsible for mitochondrial health. Our AI has been trained and refined by learning from thousands of genetic variants found in the human population. By simply sequencing your DNA we will be able to predict whether your mutations and variants of these key proteins put your health at risk.
Connect directly with our scientific team to discuss assay development, AI screening methodology, or partnership opportunities.
